Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Merck-and-Company stock

Learn how to easily invest in Merck-and-Company stock.

Merck-and-Company is a drug manufacturers-general business based in the US. Merck-and-Company shares (MRK) are listed on the NYSE and all prices are listed in US Dollars. Merck-and-Company employs 67,000 staff and has a trailing 12-month revenue of around $59 billion.

How to buy Merck-and-Company stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – MRK. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Merck-and-Company stock price (NYSE: MRK)

Use our graph to track the performance of MRK stocks over time.

Merck-and-Company shares at a glance

Information last updated 2023-01-25.
Latest market close$106.09
52-week range$70.61 - $115.49
50-day moving average $108.72
200-day moving average $94.78
Wall St. target price$116.96
PE ratio 17.9967
Dividend yield $2.72 (2.66%)
Earnings per share (TTM) $6.03

Buy Merck-and-Company stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Merck-and-Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Merck-and-Company price performance over time

Historical closes compared with the close of $106.09 from 2023-01-30

1 week (2023-01-24) -2.24%
1 month (2022-12-30) -4.38%
3 months (2022-10-31) 4.83%
6 months (2022-07-29) 18.75%
1 year (2022-01-27) 31.66%
2 years (2021-01-29) 37.65%
3 years (2020-01-31) 24.26%
5 years (2018-01-31) 79.05%

Is Merck-and-Company stock undervalued or overvalued?

Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merck-and-Company's P/E ratio

Merck-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Merck-and-Company shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Merck-and-Company's PEG ratio

Merck-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.359. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Merck-and-Company's EBITDA

Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $24.1 billion.

The EBITDA is a measure of a Merck-and-Company's overall financial performance and is widely used to measure a its profitability.

Merck-and-Company financials

Revenue TTM $59 billion
Operating margin TTM 34.51%
Gross profit TTM $35.5 billion
Return on assets TTM 12.68%
Return on equity TTM 38.15%
Profit margin 25.88%
Book value $17.55
Market capitalisation $275.1 billion

TTM: trailing 12 months

Merck-and-Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Merck-and-Company's total ESG risk score

Total ESG risk: 28.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-Company's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Merck-and-Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Merck-and-Company's environmental score

Environmental score: 3.15/100

Merck-and-Company's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Merck-and-Company's social score

Social score: 15.55/100

Merck-and-Company's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Merck-and-Company's governance score

Governance score: 12.65/100

Merck-and-Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Merck-and-Company's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-Company hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Merck & Company Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.35
Total ESG percentile 47.16
Environmental score 3.15
Environmental score percentile 4
Social score 15.55
Social score percentile 4
Governance score 12.65
Governance score percentile 4
Level of controversy 3

Merck-and-Company share dividends

37%

Dividend payout ratio: 36.55% of net profits

Recently Merck-and-Company has paid out, on average, around 36.55% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.66% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 2.66% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $2.72 per share.

While Merck-and-Company's payout ratio might seem fairly standard, it's worth remembering that Merck-and-Company may be investing much of the rest of its net profits in future growth.

Merck-and-Company's most recent dividend payout was on 8 January 2023. The latest dividend was paid out to all shareholders who bought their shares by 13 December 2022 (the "ex-dividend date").

Have Merck-and-Company's shares ever split?

Merck-and-Company's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-Company shares which in turn could have impacted Merck-and-Company's share price.

Merck-and-Company share price volatility

Over the last 12 months, Merck-and-Company's shares have ranged in value from as little as $70.6102 up to $115.49. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-Company's is 0.3931. This would suggest that Merck-and-Company's shares are less volatile than average (for this exchange).

Merck-and-Company overview

Merck & Co. , Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.

Frequently asked questions

What percentage of Merck-and-Company is owned by insiders or institutions?
Currently 0.107% of Merck-and-Company shares are held by insiders and 76.481% by institutions.
How many people work for Merck-and-Company?
Latest data suggests 67,000 work at Merck-and-Company.
When does the fiscal year end for Merck-and-Company?
Merck-and-Company's fiscal year ends in December.
Where is Merck-and-Company based?
Merck-and-Company's address is: 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
What is Merck-and-Company's ISIN number?
Merck-and-Company's international securities identification number is: US58933Y1055
What is Merck-and-Company's CUSIP number?
Merck-and-Company's Committee on Uniform Securities Identification Procedures number is: 589339209

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site